After Hours 21 Jan 2026: B8F.DE Biofrontera AG (XETRA) €6.80 on 45,797 volume
The B8F.DE stock exploded in after-hours trading, closing at €6.80 on 45,797 shares as volume surged well above the 50-day average. This move followed an open at €0.37 and a previous close of €0.32, producing a one-day change of €6.48 or 2000.00% on XETRA. The sharp swing reflects a very small free float (shares outstanding 3,038,430) and thin average liquidity (avg volume 605). We track catalysts, valuation, and trading risks as part of this high-volume movers update.
Price action and trading metrics for B8F.DE stock
Biofrontera AG (B8F.DE) traded between a day low €0.30 and day high €6.80 before finishing after hours at €6.80. Volume was 45,797 versus an average of 605, giving a relative volume of 75.70. Market capitalisation is roughly €20,673,478.00. The intraday open was €0.37 and previous close €0.32, which explains the reported €6.48 price change. These raw figures point to a liquidity-driven spike rather than a steady re-rating.
Valuation and fundamentals: quick B8F.DE stock metrics
On trailing metrics Biofrontera shows EPS -€0.21 and a reported PE -32.40. Price to sales is 0.64, price/book is 21.73, and enterprise value to sales is 0.58. The 50-day average price is €6.53 and the 200-day average is €9.19. CurrentRatio is 1.76 and debt/equity is 0.06, suggesting limited leverage but weak profitability. These metrics show a small-cap healthcare name with fragile earnings and value distortions after the spike.
Catalysts and likely drivers behind the B8F.DE stock move
No single confirmed corporate announcement accounts for the surge on public channels at the time of this after-hours update. Given the low float (shares outstanding 3,038,430) and average volume 605, large orders or block trades can move price sharply. Traders should watch company disclosures, regulatory filings, and US/EU product or distribution updates for Ameluz and Xepi. Sector flows for Healthcare were modest today, so idiosyncratic factors appear primary.
Technical and sector context for B8F.DE stock
From a technical angle, the jump cleared the 50-day average (€6.53) but remains below the 200-day average (€9.19). Year-to-date and multi-month returns show extreme volatility; the stock’s year high is €22.58 and year low €0.30. Compared with the Healthcare sector (avg PE 31.11, avg PS 3.57), Biofrontera’s small market cap and negative EPS place it well outside typical sector valuation bands.
Meyka AI grade and stock-grade analysis for B8F.DE stock
Meyka AI rates B8F.DE with a score out of 100: Score 58.42 — Grade C+ — Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The score reflects mixed fundamentals, low leverage, but high volatility and limited liquidity. These grades are informational only and not financial advice.
Risks, position sizing and trading checklist for B8F.DE stock
Key risks include extreme intraday volatility, thin liquidity, and negative trailing earnings. With avgVolume 605 and current volume 45,797, sudden reversals are likely. Use small position sizes, limit orders, and clear exit rules. Watch for dilution risk given small market cap €20.67m and monitor official filings for capital raises or corporate actions.
Final Thoughts
B8F.DE stock shows a dramatic liquidity-driven move after hours to €6.80 on 45,797 shares. Fundamentals (EPS -€0.21, PE -32.40) and a small market cap €20.67m support a cautious stance. Meyka AI’s forecast model projects a 12-month base-case target of €8.20, implying an upside of 20.52% versus the current price €6.80. The model also highlights wide scenario dispersion; downside risk remains material given weak earnings and thin trading. Forecasts are model-based projections and not guarantees. Traders should prioritize position limits, verify any company announcements on the Biofrontera site, and consider sector trends before allocating capital. For live order flow and alerts see the Meyka AI-powered market analysis tools and the company page on Biofrontera’s investor site.
FAQs
What caused the B8F.DE stock spike after hours
The after-hours spike in B8F.DE stock likely comes from low float and thin liquidity (avg volume 605, shares outstanding 3,038,430). Large orders or block trades can move price sharply. Check company filings for any confirmed catalysts.
How is B8F.DE stock valued versus peers
B8F.DE stock shows a price/sales of 0.64 and a negative EPS -€0.21, placing valuation outside typical Healthcare peers (avg PE 31.11). Small cap and negative earnings create valuation distortions.
What is Meyka AI’s view and forecast for B8F.DE stock
Meyka AI rates B8F.DE C+ (58.42) with a HOLD suggestion. The forecast model projects a 12-month base-case target of €8.20, implying 20.52% upside from €6.80. Models are projections, not guarantees.
Should traders buy B8F.DE stock after the surge
Buying after a liquidity-driven surge carries high risk. Use small position sizes, limit orders, and wait for confirmation such as sustained volume or company disclosures before increasing exposure.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
